Investing

Rigel Pharmaceuticals : RIGL

RIGL

Stock Data

$29.40

$0.50 (1.73%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Rigel Pharmaceuticals is a biotech firm focused on creating treatments for patients with blood disorders and cancer. Its flagship products include Tavalisse, for chronic immune thrombocytopenia, and Rezlidhia, targeting a specific form of acute myeloid leukemia. The company is also exploring treatments for autoimmune hemolytic anemia and COVID-19. Collaborating with institutions like Eli Lilly and The University of Texas MD Anderson Cancer Center, Rigel is at the forefront of developing innovative therapies. Founded in 1996, it is based in South San Francisco, California.

All Rigel Pharmaceuticals Articles

3 Articles

Lee Jackson | Jun 9, 2022 at 8:51 AM EDT

Thursday’s Top Analyst Upgrades and Downgrades: Affirm, Bloom Energy, Carlyle, LyondellBasell, Microsoft, Target, Tesla, Twilio and More

Thursday's top analyst upgrades and downgrades included Affirm, Bloom Energy, Carlyle, Dutch Bros, Fiserv, Hanesbrands, LyondellBasell Industries, Microsoft, Rigel Pharmaceutical,…

Chris Lange | Sep 17, 2020 at 12:37 PM EDT

Rigel Pharma Moves Forward With Midstage COVID-19 Study

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of…

Jon C. Ogg | Aug 6, 2020 at 9:12 AM EDT

Top Analyst Upgrades and Downgrades: BioNTech, Costco, Enphase, Etsy, Moderna, Novavax, Regeneron, Roku, Square, Teva, Wayfair, Zynga and More

Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair…